title: The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing-Remitting Multiple Sclerosis.
abstract: Spinal cord atrophy occurs early in the multiple sclerosis (MS) disease course, is closely related to physical disability, and is a putative neuroprotective therapeutic outcome measure.
  
  
  
  This pilot study explored glatiramer acetate (GA)'s effect on spinal cord volume in patients with relapsing-remitting MS (RRMS).
  
  
  
  Fifteen patients receiving daily subcutaneous GA were prospectively followed. At baseline, age was 43.6 ± 7.4 years, Expanded Disability Status Scale (EDSS) score was 1.4 ± 1.5, timed 25-foot walk (T25FW) was 4.7 ± 1.1 seconds, and time on GA was 2.1 ± 3.1 years. Healthy controls (n = 10) with similar age and sex to the patients were also enrolled. The spinal cord was imaged at baseline and one year later with 3T magnetic resonance imaging. An active surface method measured the C1-C7 spinal cord volume from which we calculated the normalized area.
  
  
  
  The spinal cord area showed no significant change in the MS group over one year (P = .19). Furthermore, the change in the spinal cord area did not differ significantly between the MS and control groups over one year (P = .26). In the MS group, the EDSS score (P = .44) and T25FW (P = .92) did not change significantly on-study.
  
  
  
  In this pilot study of RRMS, GA therapy was not associated with any ongoing spinal cord atrophy or any difference in the one-year rate of spinal cord area change versus healthy controls. These results paralleled the lack of clinical worsening and may reflect a treatment effect of GA. Further studies are needed to confirm these preliminary findings.
authors.affiliation: Departments of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.|Laboratory for Neuroimaging Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.|Partners MS Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Tarun
authors.initials: T
authors.lastname: Singhal
authors.affiliation: Departments of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.|Laboratory for Neuroimaging Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Shahamat
authors.initials: S
authors.lastname: Tauhid
authors.affiliation: Departments of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Shelley
authors.initials: S
authors.lastname: Hurwitz
authors.affiliation: Departments of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.|Laboratory for Neuroimaging Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Mohit
authors.initials: M
authors.lastname: Neema
authors.affiliation: Departments of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.|Departments of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.|Laboratory for Neuroimaging Research, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.|Partners MS Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Rohit
authors.initials: R
authors.lastname: Bakshi
mesh_terms: D000328:Adult; D001284:Atrophy; D005260:Female; D000068717:Glatiramer Acetate / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D009929:Organ Size; D010865:Pilot Projects; D013116:Spinal Cord / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology*
chemical_list: D018696:Neuroprotective Agents; D000068717:Glatiramer Acetate
keywords: MRI; glatiramer acetate; multiple sclerosis; spinal cord atrophy